Clin2
NCT07292519Likely a fitNot yet recruiting

Tirzepatide and counseling for alcohol use and weight

Alcohol Use Disorder (AUD)Overweight or ObeseComorbidities and Coexisting Conditions

Treatments studied

Part of Hormones & metabolism, Mental health clinical trials.

This study tests whether a weekly injection of tirzepatide (a medicine for weight and blood sugar) combined with cognitive-behavioral therapy (counseling) can help people with alcohol use disorder who are also overweight or obese. By reducing alcohol cravings and supporting weight loss, the treatment aims to improve both drinking and health outcomes.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
46 people
Ages
21 years to 75 years
Study type
Interventional

Who can take part

  • You are between 21 and 75 years old
  • You have a moderate to severe alcohol use disorder (at least 4 symptoms in the past year) and drink heavily (60g alcohol/day for men, 40g for women)
  • Your body mass index (BMI) is 27 or higher (overweight or obese)
  • You are motivated to cut back or stop drinking but are not currently in treatment for alcohol use
  • You do not have diabetes, serious mental illness, or a history of severe alcohol withdrawal (like seizures or delirium)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06727331Recruiting· Phase 2
Tirzepatide for alcohol use recovery

This trial tests if tirzepatide, a medication that helps with appetite and blood sugar, can help people with alcohol use disorder drink less or stop drinking. You would visit the clinic regularly and receive the drug or a placebo.

Boston, Massachusetts
NCT07559500Recruiting· Phase 1
Study of tirzepatide for alcohol use disorder

This trial tests if tirzepatide, a diabetes drug, affects brain chemistry linked to alcohol use. Researchers want to see if it can help people with mild-to-moderate alcohol use disorder who also have tried stimulants.

Bethesda, Maryland
NCT06994338Recruiting· Phase 2
Tirzepatide for alcohol use disorder

This study tests whether a medication called tirzepatide (a once-weekly injection) can help people reduce their alcohol consumption. It is for people who drink heavily, have a high BMI, and are actively seeking help to drink less.

Los Angeles, California
NCT06939088Recruiting· Phase 2
Tirzepatide for alcohol reduction in schizophrenia

This trial tests if tirzepatide, a once-weekly injection, can help reduce heavy drinking in people who have both schizophrenia and alcohol use disorder. If you struggle with alcohol and have stable schizophrenia, this study may offer a new treatment option.

Aalborg, Denmark
NCT07046819Recruiting· Phase 2
Tirzepatide for liver disease linked to alcohol use

This trial tests if tirzepatide, a medication that helps with weight and blood sugar, can improve liver health in people with alcohol use disorder who also have fatty liver disease. It aims to reduce liver fat and related risks.

Bethesda, Maryland
NCT07693608Enrolling by invitation· Phase 2
Tirzepatide for weight loss in stimulant use disorder

This trial tests whether a weekly injection called tirzepatide (a diabetes and weight-loss medication) can help people with obesity and stimulant use disorder reduce stimulant use and lose weight. It aims to see if treating both conditions together improves outcomes.

Dallas, Texas

Hear when a new Overweight or Obese trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.